Fovinaciclib is a selective cyclin-dependent kinase (CDK) inhibitor investigated as an anticancer pharmaceutical compound. It has been studied for its ability to inhibit CDK activity involved in cell-cycle progression and tumor-cell proliferation. Fovinaciclib is also known by the development code FVP and has been investigated in oncology research.
Fovinaciclib is a specialized pharmaceutical research compound associated with oncology and targeted cancer drug development. It is primarily investigated as a CDK inhibitor and has been evaluated in preclinical and clinical research for potential anticancer applications.
CAS Number: 168101-85-5
Molecular Formula: C24H30N6O2
Molecular Weight: 434.54 g/mol
Drug Class: Cyclin-Dependent Kinase Inhibitor
Therapeutic Area: Oncology
Development Code: FVP
Fovinaciclib inhibits cyclin-dependent kinases that regulate progression through the cell cycle. Inhibition of CDK activity can interfere with phosphorylation of cell-cycle regulatory proteins, resulting in cell-cycle arrest and suppression of tumor-cell proliferation.
Fovinaciclib has been investigated for potential use in cancer treatment and is primarily relevant to oncology research. Studies have evaluated its potential activity against tumor cells through inhibition of cell-cycle regulatory pathways.
Cyclin-dependent kinases play an important role in cell proliferation and progression through different phases of the cell cycle. Fovinaciclib is investigated as a targeted research compound because inhibition of these kinases may prevent uncontrolled proliferation of cancer cells.
Fovinaciclib is a synthetic, nitrogen-containing small molecule. It has a molecular formula of C24H30N6O2 and molecular weight of 434.54 g/mol. Its chemical structure contains heterocyclic nitrogen-containing groups associated with its kinase-inhibitory activity.
Fovinaciclib API quality assessment may include identity testing by HPLC, LC-MS and spectroscopic methods, assay determination, related substances, residual solvents, water content, elemental impurities and other applicable pharmaceutical quality-control tests.
Fovinaciclib should be stored in a tightly closed container under controlled laboratory conditions and protected from excessive heat, moisture and direct light. Storage conditions should follow applicable stability data and the specification for the particular material.
Fovinaciclib is a specialized investigational compound relevant to targeted oncology research. Its CDK inhibitory activity provides a basis for studying cell-cycle regulation, tumor-cell proliferation and potential combination strategies with other anticancer agents.
Fovinaciclib is a synthetic cyclin-dependent kinase inhibitor investigated for anticancer applications. It is identified by CAS Number 168101-85-5, with molecular formula C24H30N6O2 and molecular weight 434.54 g/mol. It is primarily associated with pharmaceutical research and oncology drug development.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |